{"protocolSection": {"identificationModule": {"nctId": "NCT02111096", "orgStudyIdInfo": {"id": "15286"}, "secondaryIdInfos": [{"id": "I1R-MC-GLDJ", "type": "OTHER", "domain": "Eli Lilly and Company"}, {"id": "2013-004275-12", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus", "officialTitle": "A Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of LY2409021 Compared to Sitagliptin in Subjects With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2019-09", "overallStatus": "TERMINATED", "whyStopped": "The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-04"}, "primaryCompletionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-04-08", "studyFirstSubmitQcDate": "2014-04-08", "studyFirstPostDateStruct": {"date": "2014-04-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-03-24", "resultsFirstSubmitQcDate": "2018-03-24", "resultsFirstPostDateStruct": {"date": "2018-04-24", "type": "ACTUAL"}, "dispFirstSubmitDate": "2015-12-23", "dispFirstSubmitQcDate": "2015-12-23", "dispFirstPostDateStruct": {"date": "2016-01-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2019-09-25", "lastUpdatePostDateStruct": {"date": "2019-10-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks)."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 174, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LY2409021", "type": "EXPERIMENTAL", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.", "interventionNames": ["Drug: LY2409021", "Drug: Metformin", "Drug: Sulfonylurea"]}, {"label": "Sitagliptin", "type": "ACTIVE_COMPARATOR", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.", "interventionNames": ["Drug: Sitagliptin", "Drug: Metformin", "Drug: Sulfonylurea"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.", "interventionNames": ["Drug: Placebo", "Drug: Metformin", "Drug: Sulfonylurea"]}], "interventions": [{"type": "DRUG", "name": "LY2409021", "description": "Administered orally", "armGroupLabels": ["LY2409021"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "Administered orally", "armGroupLabels": ["Sitagliptin"]}, {"type": "DRUG", "name": "Placebo", "description": "Administered orally", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "Administered orally", "armGroupLabels": ["LY2409021", "Placebo", "Sitagliptin"]}, {"type": "DRUG", "name": "Sulfonylurea", "description": "Administered orally", "armGroupLabels": ["LY2409021", "Placebo", "Sitagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to 6 Months in Hepatic Fat Fraction", "description": "The hepatic fat fraction (HFF) was calculated by a core imaging laboratory from noncontrast magnetic resonance imaging (MRI) of the liver. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "timeFrame": "Baseline, 6 months"}], "secondaryOutcomes": [{"measure": "Change From Baseline to 6 Months in Alanine Aminotransferase Levels", "description": "Alanine aminotransferase (ALT) assessed by a central laboratory. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "timeFrame": "Baseline, 6 months"}, {"measure": "Number of Participants With Hepatobiliary Adverse Events of Special Interest (AESI)", "description": "Number of participants with ALT or AST greater than 3 times the upper limit of normal at a post-baseline visit. A summary of other non-serious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.", "timeFrame": "Baseline, 6 months"}, {"measure": "Change From Baseline to 6 Months in Fasting Lipids Levels", "description": "Lipid values (cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides) assessed by a central laboratory. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "timeFrame": "Baseline, 6 months"}, {"measure": "Change From Baseline to 6 Months in Fasting Blood Glucagon", "description": "Glucagon values assessed by a central laboratory. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "timeFrame": "Baseline, 6 months"}, {"measure": "Change From Baseline to 6 Months in Body Weight", "description": "Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "timeFrame": "Baseline, 6 months"}, {"measure": "Change From Baseline to 6 Months in Hemoglobin A1c (HbA1c)", "description": "HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, visit, baseline score, and treatment-by-visit.", "timeFrame": "Baseline, 6 months"}, {"measure": "Change From Baseline to 6 Months in Fasting Plasma Glucose", "description": "Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "timeFrame": "Baseline, 6 months"}, {"measure": "Change From Baseline to 6 Months in Blood Pressure", "description": "Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured in triplicate throughout the study. At each visit, all available blood pressure measurements for a subject were averaged to provide the blood pressure for that visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "timeFrame": "Baseline, 6 months"}, {"measure": "Change From Baseline to 6 Months in Pulse Rate", "description": "Seated pulse rate was measured in triplicate throughout the study. At each visit, all available pulse measurements for a subject were averaged to provide the pulse for that visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "timeFrame": "Baseline, 6 months"}, {"measure": "Change From Baseline to 6 Months in 7-Point Self-Monitoring of Blood Glucose (SMBG)", "description": "7-point profile consists of pre-meal and 2-hour postprandial SMBG measurements for the morning, midday, and evening meals in 1 day and at 3 AM (nocturnal blood glucose measurement). Pre-meal measurements were taken before the subject began eating the meal. Participants recorded their glucose measurements in their study diaries.", "timeFrame": "Baseline, 6 months"}, {"measure": "Population Pharmacokinetics: Apparent Clearance of LY2409021", "description": "Reported as a Population Estimate with % Standard Errors of Estimation (SEE), 5th-95th confidence interval.", "timeFrame": "Day 1 Month 1, 3, 6, 9, predose, 1 hour postdose,"}, {"measure": "Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021", "timeFrame": "Day 1 Month 1, 3, 6, 9, predose, 1 hour postdose,"}, {"measure": "Rate of Hypoglycemic Events Adjusted Per 30 Days", "description": "Documented symptomatic hypoglycemia, an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration \\<=70 mg/dL (\\<=39 mmol/L),is presented. Rate: (30 days) is calculated as: (number of episodes during the time period divided by the number of days during the time period) multiplied by 30.", "timeFrame": "Baseline through 6 months"}, {"measure": "Number of Participants With Hypoglycemic Events", "description": "Documented symptomatic hypoglycemia, an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration \\<=70 mg/dL (\\<=39 mmol/L), is presented. The number of subjects with an event are subjects who had at least one episode of documented symptomatic hypoglycemia during the time period.", "timeFrame": "Baseline through 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have been treated with a stable dose of metformin for at least 3 months and have been treated with an optimally effective and stable dose of an sulfonylurea for at least 6 months prior to screening.\n* HbA1c value between 7.0% and 10.0%, inclusive.\n* Body mass index (BMI) between 20 and 45 kilograms/square meter (kg/m\\^2), inclusive.\n\nExclusion Criteria:\n\n* Known type 1 diabetes mellitus.\n* More than 1 episode of severe hypoglycemia within 6 months prior to screening.\n* Two or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening.\n* Severe gastrointestinal disease that may significantly impact gastric emptying or motility or having undergone gastric bypass or gastric banding surgery.\n* Previous history or active diagnosis of pancreatitis.\n* Positive hepatitis B surface antigen or hepatitis C antibody.\n* Clinical signs or symptoms of liver disease, or hepatic aminotransferases (aminotransferase or alanine aminotransferase) greater than 2.0\u00d7 upper limit of normal (ULN) or elevated alkaline phosphatase (greater than ULN) unrelated to bone metabolic disease.\n* Elevated total bilirubin level (greater than ULN), clinically suspicious signs/symptoms of cirrhosis or history of cirrhosis.\n* Current diagnosis, personal history of neuroendocrine tumors, family history of any type of multiple endocrine neoplasia (MEN), or Von Hippel-Lindau.\n* Contraindications for magnetic resonance imaging.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "John Muir Health Network - The Osteoporosis Center", "city": "Concord", "state": "California", "zip": "94520", "country": "United States", "geoPoint": {"lat": 37.97798, "lon": -122.03107}}, {"facility": "Valley Endocrine, Fresno", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "National Research Institute", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Suncoast Research Group, LLC", "city": "Miami", "state": "Florida", "zip": "33135", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "New Horizon Research Center", "city": "Miami", "state": "Florida", "zip": "33175", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Clinical Research of West Florida, Inc.", "city": "Tampa", "state": "Florida", "zip": "33603", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "University of Hawaii", "city": "Honolulu", "state": "Hawaii", "zip": "96813", "country": "United States", "geoPoint": {"lat": 21.30694, "lon": -157.85833}}, {"facility": "East West Medical Institute", "city": "Honolulu", "state": "Hawaii", "zip": "96814", "country": "United States", "geoPoint": {"lat": 21.30694, "lon": -157.85833}}, {"facility": "Rocky Mountain Diabetes and Osteoporosis Center", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Cedar-Crosse Research Center", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Midwest CRC", "city": "Crystal Lake", "state": "Illinois", "zip": "60012", "country": "United States", "geoPoint": {"lat": 42.24113, "lon": -88.3162}}, {"facility": "Iderc, P.L.C.", "city": "Des Moines", "state": "Iowa", "zip": "50314", "country": "United States", "geoPoint": {"lat": 41.60054, "lon": -93.60911}}, {"facility": "Cotton O'Neil Clinic", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "Centex Studies, Inc", "city": "Lake Charles", "state": "Louisiana", "zip": "70601", "country": "United States", "geoPoint": {"lat": 30.21309, "lon": -93.2044}}, {"facility": "Cosmopolitan International Diabetes Center", "city": "Columbia", "state": "Missouri", "zip": "65212", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "Mercy Medical Research Institute", "city": "Springfield", "state": "Missouri", "zip": "65807", "country": "United States", "geoPoint": {"lat": 37.21533, "lon": -93.29824}}, {"facility": "Palm Research Center", "city": "Las Vegas", "state": "Nevada", "zip": "89148", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "SHS Clinical Research Group", "city": "Toms River", "state": "New Jersey", "zip": "08753", "country": "United States", "geoPoint": {"lat": 39.95373, "lon": -74.19792}}, {"facility": "Office:Alwine,Lk", "city": "Downingtown", "state": "Pennsylvania", "zip": "19335", "country": "United States", "geoPoint": {"lat": 40.0065, "lon": -75.70327}}, {"facility": "University Diabetes and Endocrine Consultants", "city": "Chattanooga", "state": "Tennessee", "zip": "37411", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "Dallas Diabetes Endocrine Center", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Galenos Research", "city": "Dallas", "state": "Texas", "zip": "75251", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "San Gabriel Clinical Research", "city": "Georgetown", "state": "Texas", "zip": "78626", "country": "United States", "geoPoint": {"lat": 30.63269, "lon": -97.67723}}, {"facility": "Oakwell Clinical Research", "city": "San Antonio", "state": "Texas", "zip": "78218", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Victorium Clinical Research", "city": "San Antonio", "state": "Texas", "zip": "78240", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Polyclinic", "city": "Seattle", "state": "Washington", "zip": "98104", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Athens", "zip": "11527", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Thessaloniki", "zip": "54636", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "PRADNET, Inc. Centro Especializado de Nutricion y Bariatria", "city": "Hato Rey", "zip": "00917", "country": "Puerto Rico"}, {"facility": "American Telemedicine Center", "city": "San Juan", "zip": "00917-3104", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "GCM Medical Group PSC", "city": "San Juan", "zip": "909", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Changhua", "zip": "500", "country": "Taiwan", "geoPoint": {"lat": 24.07327, "lon": 120.56276}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Yong Kung City", "zip": "71004", "country": "Taiwan"}]}, "referencesModule": {"references": [{"pmid": "28191913", "type": "DERIVED", "citation": "Kazda CM, Frias J, Foga I, Cui X, Guzman CB, Garhyan P, Heilmann C, Yang JA, Hardy TA. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes. Diabetes Obes Metab. 2017 Aug;19(8):1071-1077. doi: 10.1111/dom.12904. Epub 2017 Mar 27."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.", "accessCriteria": "A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.", "url": "https://vivli.org/"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "FG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "FG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "65"}, {"groupId": "FG001", "numSubjects": "41"}, {"groupId": "FG002", "numSubjects": "68"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "65"}, {"groupId": "FG001", "numSubjects": "41"}, {"groupId": "FG002", "numSubjects": "68"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "64"}, {"groupId": "FG001", "numSubjects": "41"}, {"groupId": "FG002", "numSubjects": "66"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Non-Compliance with Study Drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow Up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Terminated by Sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "53"}, {"groupId": "FG001", "numSubjects": "35"}, {"groupId": "FG002", "numSubjects": "54"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "BG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "BG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "68"}, {"groupId": "BG003", "value": "174"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.9", "spread": "8.33"}, {"groupId": "BG001", "value": "57.1", "spread": "8.99"}, {"groupId": "BG002", "value": "57.8", "spread": "8.21"}, {"groupId": "BG003", "value": "57.3", "spread": "8.41"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "65"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "37"}, {"groupId": "BG003", "value": "109"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "42"}, {"groupId": "BG003", "value": "91"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "25"}, {"groupId": "BG003", "value": "80"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "3"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "11"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "31"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "51"}, {"groupId": "BG003", "value": "124"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "8"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "Greece", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "16"}]}]}, {"title": "Puerto Rico", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "26"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "45"}, {"groupId": "BG003", "value": "124"}]}]}, {"title": "Taiwan", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to 6 Months in Hepatic Fat Fraction", "description": "The hepatic fat fraction (HFF) was calculated by a core imaging laboratory from noncontrast magnetic resonance imaging (MRI) of the liver. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, have usable MRI HFF data at baseline and at least 1 post-baseline time point, excluding any data collected after stopping study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "39"}, {"groupId": "OG002", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.65", "lowerLimit": "2.13", "upperLimit": "5.17"}, {"groupId": "OG001", "value": "-0.07", "lowerLimit": "-1.94", "upperLimit": "1.79"}, {"groupId": "OG002", "value": "-0.79", "lowerLimit": "-2.28", "upperLimit": "0.70"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months in Alanine Aminotransferase Levels", "description": "Alanine aminotransferase (ALT) assessed by a central laboratory. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, baseline data and at least 1 post-baseline time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "microgram per Liter (\u00b5/L)", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "39"}, {"groupId": "OG002", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.4", "lowerLimit": "4.6", "upperLimit": "14.2"}, {"groupId": "OG001", "value": "2.6", "lowerLimit": "-3.1", "upperLimit": "8.3"}, {"groupId": "OG002", "value": "-1.3", "lowerLimit": "-6.0", "upperLimit": "3.4"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Hepatobiliary Adverse Events of Special Interest (AESI)", "description": "Number of participants with ALT or AST greater than 3 times the upper limit of normal at a post-baseline visit. A summary of other non-serious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months in Fasting Lipids Levels", "description": "Lipid values (cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides) assessed by a central laboratory. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "populationDescription": "All randomized participants who received at least 1 dose of randomized study drug, have data at baseline and at least 1 post-baseline time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "millimol per liter (mmol/L)", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"title": "Cholesterol", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "38"}, {"groupId": "OG002", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.468", "lowerLimit": "0.222", "upperLimit": "0.714"}, {"groupId": "OG001", "value": "0.006", "lowerLimit": "-0.282", "upperLimit": "0.295"}, {"groupId": "OG002", "value": "0.130", "lowerLimit": "-0.110", "upperLimit": "0.371"}]}]}, {"title": "HDL Cholesterol", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "38"}, {"groupId": "OG002", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.046", "lowerLimit": "-0.008", "upperLimit": "0.100"}, {"groupId": "OG001", "value": "0.032", "lowerLimit": "-0.031", "upperLimit": "0.095"}, {"groupId": "OG002", "value": "-0.021", "lowerLimit": "-0.032", "upperLimit": "0.074"}]}]}, {"title": "Triglycerides", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "38"}, {"groupId": "OG002", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.375", "lowerLimit": "0.087", "upperLimit": "0.644"}, {"groupId": "OG001", "value": "0.078", "lowerLimit": "-0.264", "upperLimit": "0.420"}, {"groupId": "OG002", "value": "0.099", "lowerLimit": "-0.183", "upperLimit": "0.381"}]}]}, {"title": "LDL cholesterol", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.244", "lowerLimit": "0.019", "upperLimit": "0.486"}, {"groupId": "OG001", "value": "-0.075", "lowerLimit": "-0.342", "upperLimit": "0.192"}, {"groupId": "OG002", "value": "0.019", "lowerLimit": "-0.200", "upperLimit": "0.239"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months in Fasting Blood Glucagon", "description": "Glucagon values assessed by a central laboratory. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, have data at baseline and at least 1 post-baseline time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "picomol per liter (pmol/L)", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "38"}, {"groupId": "OG002", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44.06", "lowerLimit": "36.36", "upperLimit": "51.76"}, {"groupId": "OG001", "value": "3.38", "lowerLimit": "-5.64", "upperLimit": "12.41"}, {"groupId": "OG002", "value": "5.05", "lowerLimit": "-2.50", "upperLimit": "12.60"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months in Body Weight", "description": "Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, have data at baseline and at least 1 post-baseline time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "kilograms (kg)", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.37", "lowerLimit": "0.12", "upperLimit": "0.63"}, {"groupId": "OG001", "value": "-0.08", "lowerLimit": "-0.39", "upperLimit": "0.22"}, {"groupId": "OG002", "value": "-0.05", "lowerLimit": "-0.30", "upperLimit": "0.20"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months in Hemoglobin A1c (HbA1c)", "description": "HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, visit, baseline score, and treatment-by-visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, have data at baseline and at least 1 post-baseline time point, excluding data collected after stopping study drug and/or starting rescue therapy.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent of HbA1c", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.63", "lowerLimit": "-0.94", "upperLimit": "-0.32"}, {"groupId": "OG001", "value": "-0.42", "lowerLimit": "-0.80", "upperLimit": "-0.05"}, {"groupId": "OG002", "value": "0.14", "lowerLimit": "-0.15", "upperLimit": "0.45"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months in Fasting Plasma Glucose", "description": "Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug,have data at baseline and at least 1 post-baseline time point, excluding data collected after stopping study drug and/or starting rescue therapy.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "milligram per decililiter (mg/dL)", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.5", "lowerLimit": "-34.3", "upperLimit": "-6.6"}, {"groupId": "OG001", "value": "-9.4", "lowerLimit": "-26.3", "upperLimit": "7.4"}, {"groupId": "OG002", "value": "6.6", "lowerLimit": "-7.0", "upperLimit": "20.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months in Blood Pressure", "description": "Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured in triplicate throughout the study. At each visit, all available blood pressure measurements for a subject were averaged to provide the blood pressure for that visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, have data at baseline and at least 1 post-baseline time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "millimeters of mercury (mm/Hg)", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"title": "Systolic Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.1", "lowerLimit": "2.7", "upperLimit": "9.5"}, {"groupId": "OG001", "value": "1.1", "lowerLimit": "-2.9", "upperLimit": "5.2"}, {"groupId": "OG002", "value": "1.8", "lowerLimit": "-1.5", "upperLimit": "5.1"}]}]}, {"title": "Diastolic Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.9", "lowerLimit": "0.7", "upperLimit": "5.0"}, {"groupId": "OG001", "value": "0.3", "lowerLimit": "-2.3", "upperLimit": "2.9"}, {"groupId": "OG002", "value": "1.5", "lowerLimit": "-0.6", "upperLimit": "3.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months in Pulse Rate", "description": "Seated pulse rate was measured in triplicate throughout the study. At each visit, all available pulse measurements for a subject were averaged to provide the pulse for that visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\\<=8.0%, \\>8.0%), visit, baseline score, and treatment-by-visit.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, have data at baseline and at least 1 post-baseline time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "beats per minutes (bpm)", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "lowerLimit": "-0.6", "upperLimit": "3.7"}, {"groupId": "OG001", "value": "3.5", "lowerLimit": "0.9", "upperLimit": "6.0"}, {"groupId": "OG002", "value": "1.2", "lowerLimit": "-0.9", "upperLimit": "3.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months in 7-Point Self-Monitoring of Blood Glucose (SMBG)", "description": "7-point profile consists of pre-meal and 2-hour postprandial SMBG measurements for the morning, midday, and evening meals in 1 day and at 3 AM (nocturnal blood glucose measurement). Pre-meal measurements were taken before the subject began eating the meal. Participants recorded their glucose measurements in their study diaries.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, have data at baseline and at least 1 post-baseline time point, excluding data collected after stopping study drug and/or starting rescue therapy.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"title": "Morning Pre-Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "48"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.4", "spread": "40.36"}, {"groupId": "OG001", "value": "-8.13", "spread": "31.25"}, {"groupId": "OG002", "value": "-4.31", "spread": "26.69"}]}]}, {"title": "Mid-day Pre Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "47"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.43", "spread": "41.13"}, {"groupId": "OG001", "value": "-30.58", "spread": "48.98"}, {"groupId": "OG002", "value": "-9.30", "spread": "51.08"}]}]}, {"title": "Morning 2 Hour (Hr) Post Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "44"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-38.8", "spread": "47.71"}, {"groupId": "OG001", "value": "-30.76", "spread": "44.35"}, {"groupId": "OG002", "value": "-18.28", "spread": "46.20"}]}]}, {"title": "Midday 2 hr Post Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "45"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.22", "spread": "52.64"}, {"groupId": "OG001", "value": "-25.20", "spread": "61.57"}, {"groupId": "OG002", "value": "-10.49", "spread": "54.17"}]}]}, {"title": "Evening Pre Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "47"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.58", "spread": "50.78"}, {"groupId": "OG001", "value": "-16.78", "spread": "51.09"}, {"groupId": "OG002", "value": "-14.13", "spread": "50.01"}]}]}, {"title": "Evening 2 hr Post Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.36", "spread": "58.92"}, {"groupId": "OG001", "value": "-21.12", "spread": "48.19"}, {"groupId": "OG002", "value": "-9.50", "spread": "48.62"}]}]}, {"title": "Three AM", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "45"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-22.78", "spread": "42.49"}, {"groupId": "OG001", "value": "-20.12", "spread": "57.39"}, {"groupId": "OG002", "value": "0.88", "spread": "41.94"}]}]}]}, {"type": "SECONDARY", "title": "Population Pharmacokinetics: Apparent Clearance of LY2409021", "description": "Reported as a Population Estimate with % Standard Errors of Estimation (SEE), 5th-95th confidence interval.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had evaluable PK data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters per hour (L/h)", "timeFrame": "Day 1 Month 1, 3, 6, 9, predose, 1 hour postdose,", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.526", "lowerLimit": "0.454", "upperLimit": "0.598"}]}]}]}, {"type": "SECONDARY", "title": "Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021", "populationDescription": "All participants who received at least 1 dose of study drug and had evaluable PK data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters (L)", "timeFrame": "Day 1 Month 1, 3, 6, 9, predose, 1 hour postdose,", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.9", "lowerLimit": "24.5", "upperLimit": "39.3"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Hypoglycemic Events Adjusted Per 30 Days", "description": "Documented symptomatic hypoglycemia, an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration \\<=70 mg/dL (\\<=39 mmol/L),is presented. Rate: (30 days) is calculated as: (number of episodes during the time period divided by the number of days during the time period) multiplied by 30.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, have data at baseline and at least 1 post-baseline time point, excluding data collected after stopping study drug and/or starting rescue therapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "number of episodes per day", "timeFrame": "Baseline through 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.27"}, {"groupId": "OG001", "value": "0.19"}, {"groupId": "OG002", "value": "0.12"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Hypoglycemic Events", "description": "Documented symptomatic hypoglycemia, an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration \\<=70 mg/dL (\\<=39 mmol/L), is presented. The number of subjects with an event are subjects who had at least one episode of documented symptomatic hypoglycemia during the time period.", "populationDescription": "All randomized participants who received at least 1 dose of study drug, have data at baseline and at least 1 post-baseline time point, excluding data collected after study drug and/or starting rescue therapy.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "timeFrame": "Baseline through 6 months", "groups": [{"id": "OG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "68"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "description": "All randomized participants who received at least 1 dose of study drug.", "eventGroups": [{"id": "EG000", "title": "LY2409021", "description": "20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.", "seriousNumAffected": 5, "seriousNumAtRisk": 65, "otherNumAffected": 26, "otherNumAtRisk": 65}, {"id": "EG001", "title": "Sitagliptin", "description": "100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.", "seriousNumAffected": 5, "seriousNumAtRisk": 41, "otherNumAffected": 22, "otherNumAtRisk": 41}, {"id": "EG002", "title": "Placebo", "description": "Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.", "seriousNumAffected": 1, "seriousNumAtRisk": 68, "otherNumAffected": 21, "otherNumAtRisk": 68}], "seriousEvents": [{"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Small intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Abscess limb", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Device related infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Infectious colitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Malignant hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Sinus bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Type v hyperlipidaemia", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 68}]}, {"term": "Cerumen impaction", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Blindness unilateral", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Diabetic retinal oedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Eye swelling", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Glaucoma", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 5, "numAffected": 3, "numAtRisk": 68}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 68}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Polyp", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 68}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Hepatic cyst", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Allergy to vaccine", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Seasonal allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Labyrinthitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Pharyngitis streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Subcutaneous abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 4, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 68}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Vulvovaginal candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Blood pressure diastolic increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Free fatty acids increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Glomerular filtration rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 68}]}, {"term": "Heart rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Weight decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Abnormal weight gain", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Intervertebral disc degeneration", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Musculoskeletal stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Colon adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Carotid arteriosclerosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 6, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 8, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}]}, {"term": "Tension headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Microalbuminuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Atrophic vulvovaginitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 68}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Terminated, The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Eli Lilly and Company", "phone": "800-545-5979"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}